Cat. No. | Product name | CAS No. |
DC9632 |
BAY 61-3606 (dihydrochloride)
Featured
BAY 61-3606 2Hcl is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase activity (Ki= 7.5 nM) with no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src. |
648903-57-5 |
DC10660 |
BAY 61-3606 free base
Featured
BAY 61-3606 is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase activity (Ki= 7.5 nM) with no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src. |
732983-37-8 |
DC11859 |
BAY85-8501
BAY 85-8501 (BAY85-8501) is a potent, selective human neutrophil elastase (HNE) inhibitor with IC50 of 65 pM. |
1161921-82-9 |
DC9956 |
BFH772
Featured
BFH772 is a potent oral VEGFR2 inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC50 value of 3 nM. |
890128-81-1 |
DC11819 |
BMS-986142
Featured
BMS-986142 is a potent, selective, and reversible BTK (Bruton’s tyrosine kinase) inhibitor (BTK IC₅₀ = 0.5nM; human WB IC₅₀ = 90 nM). |
1643368-58-4 |
DC12030 |
BMS-986195
Featured
BMS-986195 is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK). |
1912445-55-6 |
DC7675 |
BX-471(ZK 811752)
Featured
BX471 is a potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1); exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4. |
217645-70-0 |
DC10357 |
Cenerimod
Cenerimod (ACT-334441) is a potent and orally available sphingosine 1-phosphate 1 receptor (S1P1) agonist extracted from patent WO 2016184939 A1 and WO 2011007324 A1, example 1, with an EC50 of 2.7 nM. |
1262414-04-9 |
DC9154 |
Cetirizine 2HCl
Cetirizine 2Hcl, a second-generation antihistamine, is a major metabolite of hydroxyzine, and a racemic selective H1 receptor inverse agonist used in the treatment of allergies, hay fever, angioedema, and urticaria. |
83881-52-1 |
DC9582 |
Cilomilast
Cilomilast(SB 207499; Ariflo) is a potent PDE4 inhibitor with IC50 of about 110 nM, has anti-inflammatory activity and low central nervous system activity. |
153259-65-5 |
DC11154 |
CR6086
CR6086 (CR-6086) is a potent, selective prostaglandin E2 receptor 4 (EP4) antagonist with Ki of 16.6 nM (hEP4 receptor), inhibits PGE2-stimulated cAMP production with IC50 of 22 nM. |
|
DC8997 |
Cromolyn sodium
Cromolyn sodium is an antiallergic drug. |
15826-37-6 |
DC9689 |
Danirixin (GSK1325756)
Featured
Danirixin(GSK1325756) is a selective CXCR2 antagonist. |
954126-98-8 |
DC8171 |
Decernotinib (VX-509,adelatinib)
Featured
Decernotinib(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays. |
944842-54-0 |
DC11890 |
Delgocitinib
Featured
Delgocitinib (JTE-052, LEO 124249) is a potent, selective, orally active, pan-JAK inhibitor with IC50 of 2.8, 2.6, 13 and 58 nM for JAK1,2,3 and Tyk2, respectively. |
1263774-59-9 |
DC10141 |
E6005
Featured
E6005 potently and selectively inhibited human PDE4 activity with an IC50 of 2.8 nM and suppressed the production of various cytokines from human lymphocytes and monocytes with IC50 values ranging from 0.49 to 3.1 nM. |
947620-48-6 |
DC11398 |
Edicotinib(JNJ-40346527)
Featured
Edicotinib(JNJ-40346527)is a small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity. |
1142363-52-7 |
DC10380 |
Evobrutinib
Featured
Evobrutinib is an inhibitor of Bruton's tyrosin kinase (Btk) inhibitor extracted from patent US20140162983 example 0174. |
1415823-73-2 |
DC11278 |
Fevipiprant
Featured
Fevipiprant(QAW039) is a selective, potent, reversible competitive CRTh2 antagonist with an in vitro dissociation constant KD value of 1.1nM at the CRTh2 receptor and an IC50 value of 0.44 nM for inhibition of PGD2-induced eosinophil shape change. |
872365-14-5 |
DC8936 |
Fingolimod
Fingolimod(FTY720 free base) is a S1P antagonist with IC50 of 0.033 nM. |
162359-55-9 |
DC3154 |
Fingolimod HCl(FTY-720)
Featured
FTY720 (Fingolimod, Gilenya) is a S1P antagonist with IC50 of 0.033 nM. |
162359-56-0 |
DC9942 |
GDC-0853(RG7845)
Featured
GDC-0853 is orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. |
1434048-34-6 |